<DOC>
	<DOCNO>NCT00559871</DOCNO>
	<brief_summary>The purpose study determine whether Fipamezole effective treatment levodopa-induced dyskinesia advance Parkinson 's disease .</brief_summary>
	<brief_title>Safety Efficacy Study Fipamezole Treatment Motor Dysfunctions Parkinson 's Disease</brief_title>
	<detailed_description>This study multi-center , double-blind , placebo-controlled , multiple dose escalating , safety , tolerance , pharmacokinetics , efficacy study fipamezole administer Parkinson 's disease patient concomitantly treat combination product levodopa dopamine decarboxylase inhibitor ( DDI ) possible antiparkinson medication . Approximately 30 site US India participate study . The patient randomize one four treatment arm receive either fixed ascending dos Fipamezole ( 30 90 mg tid ) placebo . For efficacy assessment , levodopa-induced dyskinesia assess use standardise rating scale . Time spend 'Off ' state 'On ' state without dyskinesia , 'On ' non-troublesome dyskinesia 'On ' troublesome dyskinesia , assess use patient diary . Impact dyskinesia daily activity quantify use PDYS-26 questionnaire . To explore potential positive negative impact Fipamezole cognitive function , study include two cognitive test . Finally , study include investigator assessment CGI-I scale dyskinesia , Parkinson 's disease , clinical condition general .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Main Idiopathic Parkinson 's disease . Levodopa/DDI associate peakdose dyskinesia least moderately disable present ≥25 % wake day ( UPDRS part IV , item 32 33 , ≥ 2 ) . Stable Parkinson 's medication least 1 month prior randomization . Hoehn Yahr Stages 1 4 'Off ' period . Demonstrated ability comprehend give inform consent . Ability complete patient diary . Main Other clinically significant condition apart typically associate Parkinson 's disease . Intake medication associate exacerbation dyskinesia extrapyramidal side effect tardive dyskinesia induction liver enzymes ; neuroleptic ; specify drug know substantially metabolize follow cytochrome P450 isoenzymes : 1A2 , 2B6 , 2C19 , 2C9 , 2D6 , 2E1 . Use St. John 's Wort Ginkgo Biloba within 48 hrs prior randomization last treatment day study medication . Intake investigational drug within 30 day prior initial screening .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>dyskinesia</keyword>
	<keyword>movement disorder</keyword>
	<keyword>basal ganglion disease</keyword>
	<keyword>JP-1730</keyword>
	<keyword>Parkinson</keyword>
	<keyword>end-of-dose wearing</keyword>
	<keyword>fluctuation</keyword>
</DOC>